Inhibitor compounds of phosphodiesterase type 10A

US9163019B2 · kind B2 · utility

Assignees

• Abb Vie Deutschland Gmbh & Co. KG · DE
• Abb Vie Inc. · US

Inventors

• Hervé Geneste · Schifferstadt, DE
• Michael Ochse · Wiesbaden, DE
• Karla Drescher · Ludwigshafen, DE
• Berthold Behl · Ludwigshafen, DE
• Loic Laplanche · Ludwigshafen, DE
• Jurgen Dinges · Wadsworth, US
• Clarissa Jakob · North Chicago, US

Key dates

• Filing date: Mar 13, 2014
• Grant date: Oct 20, 2015
• Expiry date: Mar 13, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof:In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims.The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.